ストックスクリーナーアプリを入手
1.35
2.27%
0.03
アフターアワーズ：
1.37
0.02
+1.48%
Biomea Fusion Inc (BMEA) 最新ニュース
Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - Kalkine Media
Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union
Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada
Biomea Fusion doses first patient in icovamenib-semaglutide study - Investing.com
Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss - Stock Titan
Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA - MarketBeat
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Expects Stronger Earnings for Biomea Fusion - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion Stock (BMEA) Opinions on Clinical Milestones and Liquidity Concerns - Quiver Quantitative
Icovamenib clinical enrollment opens for type 2 diabetes study, Biomea Fusion initiates - Traders Union
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Citizens JMP Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Biomea Fusion Inc (BMEA) Stock News Today - TradingKey
Biomea Fusion explores new scientific approaches to diabetes treatment - Traders Union
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Biomea Fusion, Inc. Stock 12‑Month Price Target Cut to $6.71, Implies 433% Upside - TradingView
Biomea Fusion, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea Fusion Q2 loss narrows, cash runway into Q2 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) trims R&D, discloses going concern risk - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
BMEA: Net loss narrowed and clinical trial progress supports cash runway into Q2 2027 - TradingView
Biomea Fusion (BMEA) Gains 2.56% to $1.2 as Key Levels Come into FocusStock Surge Alerts - dars.gov.et
Participants sought for type 2 diabetes trial evaluating icovamenib, Biomea Fusion announces - Traders Union
Biomea Fusion Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
BMEA Q2'26 Earnings: EPS estimate is (0.22) USD - tradingview.com
Biomea Fusion (BMEA) to Post Earnings on Tuesday - MarketBeat
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BMEA|Biomea Fusion Inc|Price:1.250|Chg%:-0.010 - TradingKey
Biomea Fusion Inc (BMEA) Balance Sheet - TradingKey
Biomea Fusion Inc (BMEA) Income Statement - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BMEA|Biomea Fusion Inc|Price:1.265|Chg%:+0.015 - TradingKey
BMEA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TradingKey - TradingKey
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
Biomea Fusion Market Sentiment - Benzinga España
Biomea Fusion(BMEA) Stock Options Chain | Quotes & News - Moomoo
Biomea Fusion, Inc. Revenue Breakdown – NASDAQ:BMEA - TradingView
Biomea Fusion launches Phase II trial for icovamenib in type 1 diabetes - Traders Union
Biomea Fusion outlines key stages involved in clinical trials for new medicines - Traders Union
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, - GuruFocus
Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting - Traders Union
Biomea Fusion Inc Financial Disclosures & SEC Filings - TradingView
Biomea Fusion Inc. (BMEA) Q1 2026 Earnings: Narrower-than-expected loss highlights cost managementDebt Analysis Report - dars.gov.et
Price to earnings forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to sales forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to book forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Enterprise value to revenue forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12% - simplywall.st
Enterprise value to EBITDA forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Enterprise value to EBIT forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Inc Actuals & Estimates (NASDAQ:BMEA) - TradingView
COVALENT-112 Phase II data boost momentum for ico, Biomea Fusion pushes first-in-class strategy - Traders Union
BMEA Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS) - The Globe and Mail
BMEA Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionEPS Surprise History - po-news-eg.net
Biomea Fusion forges new industry ties at BIO International Convention - Traders Union
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):